학술논문

The iR2 regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 study
Document Type
Article
Source
In: eClinicalMedicine. (eClinicalMedicine, February 2023, 56)
Subject
Language
English
ISSN
25895370